NCT04399980View on ClinicalTrials.gov

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
COVID 19SARS-CoV 2Pneumonia
Interventions
DRUG

Mavrilimumab

Treatment infusion

DRUG

Placebos

Placebo infusion

Trial Locations (2)

33331

Cleveland Clinic Florida, Weston

44195

Cleveland Clinic Health System, Cleveland

Sponsors
All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, Ltd.

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT04399980 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Biotech Hunter | Biotech Hunter